Zotarolimus

From Wikipedia, the free encyclopedia

Zotarolimus
Systematic (IUPAC) name
1,18-Dihydroxy-19,30-dimethoxy-12-[2-(3-methoxy-4-tetrazol-1-yl-cyclohexyl)-1-methyl-ethyl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
Identifiers
CAS number 221877-54-9
ATC code  ?
PubChem  ?
Chemical data
Formula C52H79N5O12 
Mol. mass  ?
Synonyms (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Zotarolimus (INN) is an immunosupressant. It is a semi-synthetic derivative of rapamycin.


Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04)
Monoclonal antibodies
TNF inhibitors (Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
-imus
-cept (Fusion protein)
Other